Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MARIETTA, Ga., March 14, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, is proud to announce the Yamaha Outdoor Access Initiative (OAI) contributed over $1 million in grant awards in 2023,...
-
MARIETTA, Ga., March 07, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, is thrilled to announce significant expansions to its bLU cRU program for the 2024 Side-by-Side (SxS) and ATV racing...
-
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Linear Resistors Market (2023 Edition): Analysis By Type, Material (Carbon Film, Metal Film, Metal Oxide Film, Others), By Application, By...
-
OSLO, Norway, 15 February 2024 -- Ensurge Micropower (OSE: ENSU, and OTCQB: ENMPY) (“Ensurge” or the “Company”) today announces that it has successfully manufactured fully functional solid state...
-
MARIETTA, Ga., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, proudly announces a groundbreaking chapter in outdoor access with the Yamaha Outdoor Access Initiative (OAI) awarding two...
-
Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point immunotherapeutic candidates with DEKA’s...
-
PITTSBURGH, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a leader in optical sensing for consumer electronics, today announced the introduction of dot projector modules for depth...
-
Pune, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The Surface Mount Technology (SMT) Market, as per the SNS Insider report, achieved a valuation of USD 5.9 billion in 2022. Projections indicate a substantial...
-
Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses. Emergex is...
-
Earlier this year, Emergex submitted a notification to the FDA regarding the transfer of ownership of Zosano Pharma’s Microneedle Array Patch (MAP) epidermal drug delivery system to Emergex itself...